• Pocket Analyst Logo
  • Search
  • Chat
  • News
  • Discover
  • Portfolio
  • Contact
  • Sign In
Conversations
  • Sign up to save conversations
    flag
    ASX200
    -0.21%
    PFE logo
    Pfizer Inc.
    PFEflag
    Latest News
    positive

    Pfizer's quarterly EPS was $0.92, beating estimates of $0.67 by 38.23%.

    Last generated Jun 22, 2025

    Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

    Market Cap.$135.77B
    SectorHealthcare
    IndustryDrug Manufacturers - General
    PE Ratio17.23
    Profit Margin12.59%
    Beta0.49
    Dividend Yield7.12%
    Consensus RatingN/A
    Dividends
    Dividend Amount (TTM)1.70
    Dividend Yield (TTM)7.09%
    Payout Ratio1.22%
    Valuation
    Price to Earnings (PE) Ratio17.29
    Price to Sales (PS) Ratio 2.18
    Price to Book (PB) Ratio 1.51
    Price to Free Cash Flow (PFCF) Ratio 12.15
    Price to Earnings Growth (PEG) Ratio -8.13
    Profitability
    Profit Margin12.59%
    Gross Margin67.39%
    Return on Equity8.78%
    Return on Assets3.78%
    Finances
    Debt to Equity Ratio0.68
    Current Ratio1.26
    Cash Ratio0.04
    Growth
    Earnings Per Share Growth (5Y)12.70%
    Revenue Growth (5Y)51.83%